Creative Medical Tech Faces 2025 Losses Amid FDA Trials
Creative Medical Technology outlines 2025 losses, trials
Creative Medical Technology’s 2025 report shows an operating loss, modest cash of about $7.2M, and minimal revenue, while advancing FDA-cleared trials, Fast Track CELZ-201-DDT, and iPSC/AI partnerships targeting diabetes, back pain and other regenerative indications.
Creative Medical Technology reported significant 2025 operating losses with modest cash reserves of $7.2 million and minimal revenue. However, the company is advancing FDA-cleared trials including Fast Track CELZ-201-DDT and iPSC/AI partnerships targeting diabetes, back pain, and other regenerative medicine indications.
Original Article
Read full article on sourceExplore More
Related News
pH7 Technologies: C$55 Million Series B Closed To Scale Critical Minerals Extraction Technology
Pulse 2.0 · 2026.04.15
Top 12 Front End Technologies for 2026
2026.04.15
CoinHix Revolutionizing Coin Collecting with AI Technology
Respect My Region · 2026.04.15
Latest Advances In Agriculture Technology Boosting Yields
2026.04.15
The NEST shifts to technology
Mmegi Online · 2026.04.15
7 Ways Technology Helps Auto Dealerships Succeed
NADA Home Page | NADA · 2026.04.14